Clinical Trial Update: RHODOS Follow-up Single-visit Study

View source ↗

Summary

The RHODOS follow-up single-visit trial in Leber's hereditary optic neuropathy has completed, according to an update from Santhera.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• Raxone (idebenone)

Snippet

Sponsor: Santhera Pharmaceuticals | Conditions: Leber's Hereditary Optic Neuropathy | Status: COMPLETED